Novavax Capital Surpluse from 2010 to 2024

NVAX Stock  USD 8.72  0.10  1.16%   
Novavax Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2024. During the period from 2010 to 2024, Novavax Capital Surpluse regression line of annual values had r-squared of  0.85 and arithmetic mean of  1,666,687,880. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
3.8 B
Current Value
3.9 B
Quarterly Volatility
1.1 B
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Novavax over the last few years. It is Novavax's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Novavax Capital Surpluse Regression Statistics

Arithmetic Mean1,666,687,880
Geometric Mean1,206,974,890
Coefficient Of Variation81.11
Mean Deviation1,174,431,040
Median1,020,457,000
Standard Deviation1,351,785,849
Sample Variance1827325T
Range3.7B
R-Value0.92
Mean Square Error286485.1T
R-Squared0.85
Slope279,401,419
Total Sum of Squares25582549.8T

Novavax Capital Surpluse History

2024B
20233.9 B
20213.4 B
20202.5 B
20191.3 B
20181.1 B
2017B

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse3.9 BB

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.